双示踪剂PET/CT预测无功能胰腺神经内分泌肿瘤侵袭性
该前瞻性研究纳入31例无功能胰腺神经内分泌肿瘤患者,行68Ga-DOTANOC和18F-FDG PET/CT并与病理对比。18F-FDG PET/CT阳性与肿瘤Ki-67相关(P=0.021),对潜在侵袭性肿瘤的阳性预测值为78%,阴性预测值为69%;68Ga-DOTANOC的Krenning评分也与Ki-67相关(P=0.013)。
要点
- 18F-FDG PET/CT有助于预测NF-PNET的肿瘤分级,但不能预测淋巴结转移。
- 18F-FDG阳性的NF-PNET患者应考虑手术转诊。
- 68Ga-DOTANOC的Krenning评分可预测病理分级,具有预后价值。
核心结论
- 18F-FDG PET/CT可预测NF-PNET的肿瘤分级,但对淋巴结转移无预测价值。
- 68Ga-DOTANOC PET/CT的Krenning评分可预测病理分级,具有预后价值。
- 18F-FDG阳性的NF-PNET患者应转诊手术。
研究设计与样本
- 前瞻性研究纳入31例NF-PNET患者(90%无症状),行18F-FDG和68Ga-DOTANOC PET/CT。
- 后续行手术(n=20)、超声内镜细针穿刺活检(n=2)或随访(n=9),平均随访31.3个月。
- 影像结果与组织病理学对比,PET/CT上高于背景且非生理性摄取灶视为肿瘤组织。
主要发现
- 18F-FDG PET/CT在G1中阳性19%(3/16)、G2中63%(5/8)、高分化G3中1/1;68Ga-DOTANOC在G1中阳性94%、G2中100%、高分化G3中1/1。
- 淋巴结转移患者中2/6(33%)为18F-FDG阳性。
- 18F-FDG PET/CT与肿瘤Ki-67相关(P=0.021),Krenning评分与Ki-67相关(P=0.013)。
- 18F-FDG阳性肿瘤显著大于阴性肿瘤(P=0.012);18F-FDG PET/CT检测潜在侵袭性肿瘤(G2、G3或LN+ PNET)的阳性预测值78%,阴性预测值69%。
关键数值与推荐
- 18F-FDG PET/CT对潜在侵袭性肿瘤的阳性预测值78%,阴性预测值69%。
- 18F-FDG PET/CT阳性率:G1为19%(3/16),G2为63%(5/8),高分化G3为1/1。
- Krenning评分与Ki-67相关(P=0.013),18F-FDG PET/CT与Ki-67相关(P=0.021)。
临床怎么用
- 对NF-PNET患者行18F-FDG PET/CT以辅助预测肿瘤分级。
- 18F-FDG阳性的NF-PNET患者应考虑转诊手术。
- 68Ga-DOTANOC PET/CT的Krenning评分可用于预后评估。
局限性
- 样本量较小(31例患者,53个病灶)。
- 18F-FDG PET/CT不能预测淋巴结转移(仅2/6淋巴结转移患者FDG阳性)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Predicting the aggressive behavior of non-functional pancreatic neuroendocrine tumors (NF-PNET) remains controversial. We wanted to explore, in a prospective setting, whether the diagnostic accuracy can be improved by dual-tracer functional imaging 68Ga-DOTANOC and 18F-FDG-PET/CT in patients with NF-PNETs. METHODS: Thirty-one patients with NF-PNET (90% asymptomatic) underwent PET-imaging with 18F-FDG and 68Ga-DOTANOC, followed by surgery (n = 20), an endoscopic ultrasonography and fine-needle biopsy (n = 2) or follow-up (n = 9). A focal activity on PET/CT greater than the background that could not be identified as physiological activity was considered to indicate tumor tissue. The imaging results were compared to histopathology. The mean follow-up time was 31.3 months. RESULTS: Thirty-one patients presented a total of 53 lesions (40 histologically confirmed) on PET/CT. Thirty patients had a 68Ga-DOTANOC-positive tumor (sensitivity 97%) and 10 patients had an 18F-FDG-positive tumor. In addition, one 68Ga-DOTANOC-negative patient was 18F-FDG-positive. 18F-FDG-PET/CT was positive in 19% (3/16) of the G1 tumors, 63% (5/8) of the G2 tumors and 1/1 of the well-differentiated G3 tumor. 68Ga-DOTANOC-PET/CT was positive in 94% of the G1 tumors, 100% of the G2 tumors and 1/1 of the well-differentiated G3 tumor. Two out of six (33%) of the patients with lymph node metastases (LN+) were 18F-FDG-positive. The 18F-FDG-PET/CT correlated with tumor Ki-67 (P = 0.021). Further, the Krenning score correlated with tumor Ki-67 (P = 0.013). 18F-FDG-positive tumors were significantly larger than the 18F-FDG-negative tumors (P = 0.012). 18F-FDG-PET/CT showed a positive predictive value of 78% in the detection of potentially aggressive tumors (G2, G3, or LN + PNETs); the negative predictive value was 69%. CONCLUSIONS: 18F-FDG-PET/CT is useful to predict tumor grade but not the LN+ of NF-PNETs. Patients with 18F-FDG-avid NF-PNETs should be referred for surgery. The 68Ga-DOTANOC-PET/CT also has prognostic value since the Krenning score predicts the histopathological tumor grade. TRIAL REGISTRATION: The study has been registered at ClinicalTrials.gov; Non-functional Pancreatic NET and PET imaging, NCT02621541.
引用
- Majala S, Seppänen H, Kemppainen J, et al. Prediction of the aggressiveness of non-functional pancreatic neuroendocrine tumors based on the dual-tracer PET/CT. EJNMMI Res. 2019. PMID: 31872324. doi:10.1186/s13550-019-0585-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。